Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 4
Submit an article Journal homepage
144
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Report of four acute myeloid leukemia patients with sustained complete remission with less frequent administration of decitabine and venetoclax

Ahmed AribiDepartment Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USACorrespondence[email protected]
,
Amandeep SalhotraDepartment Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USAORCID Iconhttps://orcid.org/0000-0002-9302-5041
ORCID Icon,
Brian BallDepartment Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA
,
Anthony SteinDepartment Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA
,
Guido MarcucciDepartment Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA
&
Vinod PullarkatDepartment Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA
Pages 897-899 | Received 05 Aug 2022, Accepted 07 Feb 2023, Published online: 27 Feb 2023

References

  • Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487–494.
  • Chao DT, Korsmeyer SJ. BCL-2 family: regulators of cell death. Annu Rev Immunol. 1998;16:395–419.
  • Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106–1117.
  • DiNardo CD, Pollyea DA, Jonas BA, et al. Updated safety and efficacy of venetoclax with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2017;130(Suppl 1):2628.
  • DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216–228.
  • DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17.
  • DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629.
  • Papayannidis C, Nanni J, Cristiano G, et al. Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents. Eur J Haematol. 2022;108(6):449–459.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.